Earnings ·
Cartesian Therapeutics reported financial results for the quarter ended June 30, 2026, on August 6, 2026
RNACCartesian Therapeutics, Inc.
Cartesian Therapeutics reported financial results for the quarter ended June 30, 2026, on August 6, 2026. The company posted net income of $15.8 million, or $0.47 per share, compared to $15.9 million in the prior year period. Cash and cash equivalents stood at approximately $149.3 million as of June 30, 2026, extending its operational runway into 2028 following a credit facility with K2 HealthVentures. The company provided business updates on its Descartes-08 pipeline, noting that the Phase 3 AURORA trial in myasthenia gravis is advancing with data expected in the first quarter of 2027 and a BLA filing planned for mid-2027. Additionally, Cartesian announced a strategic partnership with WestGene BioPharma to explore an in vivo CAR-T platform, with Phase 1 data anticipated in the first half of 2027. Cartesian Therapeutics is a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases.